CN113759125A - Urinary uteroglobin and application of polypeptide fragments thereof in burn - Google Patents
Urinary uteroglobin and application of polypeptide fragments thereof in burn Download PDFInfo
- Publication number
- CN113759125A CN113759125A CN202010504360.0A CN202010504360A CN113759125A CN 113759125 A CN113759125 A CN 113759125A CN 202010504360 A CN202010504360 A CN 202010504360A CN 113759125 A CN113759125 A CN 113759125A
- Authority
- CN
- China
- Prior art keywords
- uteroglobin
- burn
- urine
- antibody
- polypeptide fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides urine Uteroglobin (Uteroglobin) and application of a polypeptide fragment thereof, in particular to application of the urine Uteroglobin and the polypeptide fragment thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. The burn is an important common wound in daily life, about 5000-100000 people burn in every 100 million people every year, according to the statistics of the world health organization, more than 30 million people die of burn patients all year around the world, and the survival rate of the serious burn treatment is still at a lower level. The present invention has been confirmed by studies that urinary uteroglobin and its polypeptide fragments are expressed more in burn patients than in healthy persons (normal control group), and the degree of increase increases as the degree of burn increases. Can be used for auxiliary diagnosis and disease condition monitoring of burn patients. The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the urine uteroglobin and the polypeptide fragments thereof.
Description
Technical Field
The invention relates to urine uteroglobin and a new application of polypeptide fragments thereof, in particular to the application of the urine uteroglobin and the polypeptide fragments thereof in burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Burn refers to the injury of skin, tissue and even deep viscera of human body caused by chemical substances such as flame, high-temperature gas, scorching solid or liquid, radioactive rays, electric energy, strong acid and strong alkali, etc., and is a systemic comprehensive disease. After burn, a large amount of reactions such as necrosis, infection, shock, blood coagulation dysfunction and the like of wound tissues can cause a series of pathophysiological changes of organisms. Burns of different degrees have different influences on human bodies, serious burns can damage the environment in the human bodies, the burn patients have pathophysiological changes of complexity of various systems, and relevant detection indexes can correspondingly change along with the difference of the severity of the burns. Timely detection of changes in these indices can provide valuable reference for clinicians in many areas, such as disease diagnosis, disease judgment, treatment selection, and patient prognosis assessment.
However, patients with severe burns have poor skin integrity, and clinical use of hematological tests as invasive tests on the skin in such patients has presented difficulties, and repeated blood draw tests can also exacerbate patient pain. Urine as ultrafiltrate of blood contains abundant biological information, and the collection process has the advantages of non-invasive and convenient operation, and the like, which is particularly obvious in the detection of burn patients. The biomarker which is helpful for burn diagnosis and reflects disease change is searched in urine, so that the life quality and compliance of burn patients can be improved, the pain of blood collection for many times is relieved, and a reference basis which is favorable for disease diagnosis and treatment is better provided for clinicians.
Uteroglobin (UG) is a member of the secretoglobin superfamily, a globular homodimer with each subunit consisting of four alpha helices, and its role in maintaining homeostasis has received much attention. The research shows that the uteroglobin has a plurality of biological functions, such as the function of inhibiting monocyte and neutrophil chemotaxis, the function of anti-inflammation, the function of inhibiting platelet aggregation, etc. In the study, the expression of the uteroglobin in urine of a burn patient is up-regulated compared with that of a healthy group, the uteroglobin has a certain correlation with the burn degree, and the protein content is higher when the burn degree is more serious.
Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to relieve the pain of multiple blood sampling of burn patients, the experiment is expected to realize the diagnosis and disease monitoring of the burn patients by painless, convenient, quick and easily repeated urine detection through the research of urine protein or polypeptide on the basis of the methodology exploration of the early stage, and also lays a foundation for the further research of the urine polypeptide detection kit.
Disclosure of Invention
The invention aims to provide application of urine uteroglobin and polypeptide fragments thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Preferably, the amino acid sequence of the urine uteroglobin is shown in SEQ ID NO.1 (MKLAVTLTLV TLALCCSSAS AEICPSFQRV IETLLMDTPS SYEAAMELFS PDQDMREAGA QLKKLVDTLP QKPRESIIKL MEKIAQSSLC N); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
Preferably, the preparation is a test kit for urine uteroglobin and polypeptide fragments thereof of burn patients.
Preferably, the kit comprises one or more of an immunization method for antigen-antibody reaction and kits thereof such as aptamer antibodies or antibody fragments capable of specifically binding to uteroglobin and polypeptide fragments thereof.
Preferably, the detection method comprises mass spectrometry and related kits for directly detecting the uteroglobin and its polypeptide fragments.
Preferably, the detection method comprises a method for directly detecting the uteroglobin and related nucleic acid detection of polypeptide fragments thereof and related kits.
Preferably, the kit comprises one or more of an aptamer antibody or antibody fragment capable of specifically binding to uteroglobin and polypeptide fragments thereof.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
Preferably, the standard comprises a uteroglobin standard, a humanized tag antibody standard; preferably, the quality control product comprises: uteroglobin protein control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and patients with different burn degrees, centrifugates for 5min at 4000r/min, absorbs supernatant, determines the concentration of extracted protein by a Bradford method, and carries out SDS-PAGE enzymolysis. The Label-free mass spectrometry of the urine samples was performed by the OrbitrapFasion type mass spectrometer. And performing quantitative calculation on data obtained in the mass spectrum of the burn group and the normal control group. The differential polypeptide is screened by using the difference of protein expression amount more than 1.5 times and P <0.05 as a reference standard through statistical test. Then, the inventor identifies the differential polypeptide with statistical significance, and obtains the differential protein uteroglobin by utilizing database retrieval.
The invention proves that compared with healthy people, the uteroglobin and the polypeptide fragment thereof are highly expressed in urine of burn patients, and are increased along with the aggravation of burn degree, and the uteroglobin and polypeptide fragment thereof have better consistency with clinical diagnosis. Therefore, the method for detecting the urine uteroglobin and the polypeptide fragment thereof can be used for auxiliary diagnosis or disease condition monitoring of the burn.
The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and utilizes the urine specimen to detect the urine uteroglobin and the polypeptide fragments thereof.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
FIG. 1 is a graph showing the content of urinary uteroglobin and its polypeptide fragments in a burn group and a healthy control group.
FIG. 2 is a schematic representation of the major biological processes involved in uteroglobin.
Detailed Description
Example 1Collection and processing of urine specimens
Burn patients were selected as the burn group, and contemporary physical examiners were selected as the normal control group. 30ml samples of fresh morning urine were collected from each group of subjects after admission, and those who failed to urinate normally collected their morning urine from their catheters and placed in dry, clean containers. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Extracting protein from urine sample, and determining the concentration of extracted protein. Mass spectrometry of urine samples was performed by orbitrapfuision type mass spectrometry. And performing quantitative calculation on data obtained in the mass spectrum of the experimental group and the normal control group. The comparison among groups adopts t-test to carry out differential analysis, and differential expression proteins are screened by using the difference of protein expression quantity more than 1.5 times and taking the statistical test that P <0.05 as a reference standard.
Example 3Identification and analysis of differential Polypeptides
The database used at this time is a Uniprot _ Homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in Table 1.
Compared with healthy people, the uteroglobin is highly expressed in urine of burn patients as shown in figure 1, the main biological processes involved in the uteroglobin are shown in figure 2, and the expression of the uteroglobin in urine of normal control groups and burn groups is remarkably different and is increased along with the aggravation of the burn degree.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Zhang Man
<120> urinary uteroglobin and use of polypeptide fragments thereof in burns
<130> 1
<140> 20PUG-CN
<141> 2020-05-03
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 91
<212> PRT
<213> Human Urine
<400> 1
Met Lys Leu Ala Val Thr Leu Thr Leu Val Thr Leu Ala Leu Cys Cys
1 5 10 15
Ser Ser Ala Ser Ala Glu Ile Cys Pro Ser Phe Gln Arg Val Ile Glu
20 25 30
Thr Leu Leu Met Asp Thr Pro Ser Ser Tyr Glu Ala Ala Met Glu Leu
35 40 45
Phe Ser Pro Asp Gln Asp Met Arg Glu Ala Gly Ala Gln Leu Lys Lys
50 55 60
Leu Val Asp Thr Leu Pro Gln Lys Pro Arg Glu Ser Ile Ile Lys Leu
65 70 75 80
Met Glu Lys Ile Ala Gln Ser Ser Leu Cys Asn
85 90
Claims (9)
1. The urine uteroglobin and the polypeptide fragment thereof are applied to the preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
2. The use of claim 1, wherein the urinary uteroglobin protein has an amino acid sequence as set forth in SEQ ID No. 1; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
3. The use of claim 1, wherein the agent is a test kit for urine uteroglobin and polypeptide fragments thereof in burn patients.
4. Use according to claim 3, wherein the kit comprises one or more of an immunization method for antigen-antibody reaction and kits thereof such as aptamer antibodies or antibody fragments capable of specifically binding to uteroglobin and polypeptide fragments thereof.
5. The use according to claim 3, wherein the detection method comprises mass spectrometry and related kits for the direct detection of uteroglobin and its polypeptide fragments.
6. The use according to claim 3, wherein said detection means comprises a method for direct detection of uteroglobin and related nucleic acid detection of polypeptide fragments thereof and related kits.
7. The use according to claim 3, wherein the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
8. The use of claim 7, wherein the standard comprises a uteroglobin standard, a humanized tag antibody standard; preferably, the quality control product comprises: a uteroglobin control product and a humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
9. The use of claim 8, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010504360.0A CN113759125A (en) | 2020-06-05 | 2020-06-05 | Urinary uteroglobin and application of polypeptide fragments thereof in burn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010504360.0A CN113759125A (en) | 2020-06-05 | 2020-06-05 | Urinary uteroglobin and application of polypeptide fragments thereof in burn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113759125A true CN113759125A (en) | 2021-12-07 |
Family
ID=78783959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010504360.0A Pending CN113759125A (en) | 2020-06-05 | 2020-06-05 | Urinary uteroglobin and application of polypeptide fragments thereof in burn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113759125A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002300876B2 (en) * | 1997-05-28 | 2006-07-13 | Claragen Inc. | Use of Recombinant Human Uteroglobin in Treatment of Inflammatory and Fibrotic Conditions |
| US20130157891A1 (en) * | 2010-06-24 | 2013-06-20 | Xiao-Jun Li | Organ specific diagnostic panels and methods for identification of organ specific panel proteins |
-
2020
- 2020-06-05 CN CN202010504360.0A patent/CN113759125A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002300876B2 (en) * | 1997-05-28 | 2006-07-13 | Claragen Inc. | Use of Recombinant Human Uteroglobin in Treatment of Inflammatory and Fibrotic Conditions |
| US20130157891A1 (en) * | 2010-06-24 | 2013-06-20 | Xiao-Jun Li | Organ specific diagnostic panels and methods for identification of organ specific panel proteins |
Non-Patent Citations (1)
| Title |
|---|
| STOCKFELT, L 等: "Effects on airways of short-term exposure to two kinds of wood smoke in a chamber study of healthy humans", INHALATION TOXICOLOGY, vol. 24, no. 1, 5 January 2012 (2012-01-05), pages 47, XP008178735 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113777314A (en) | Application of urinary talin 1 and its polypeptide fragments in burns | |
| CN113759125A (en) | Urinary uteroglobin and application of polypeptide fragments thereof in burn | |
| CN114113621A (en) | Urine guanine nucleotide binding protein subunit alpha-13 and application of polypeptide fragment thereof in burn | |
| CN113777313A (en) | Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn | |
| CN114113622A (en) | Urine guanine nucleotide binding protein G(s) subunit alpha short subtype and application of polypeptide fragment thereof in burn | |
| CN114113580A (en) | Application of urine thrombomodulin and polypeptide fragment thereof in burn | |
| CN113759123A (en) | Application of urine cartilage intermediate layer protein and polypeptide fragment thereof in burn | |
| CN113777302A (en) | Application of urine complement factor D and polypeptide fragment thereof in burn | |
| CN113777316A (en) | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns | |
| CN113777315A (en) | Application of urinary ubiquitin-like protein ISG15 and its polypeptide fragments in burns | |
| CN114113600A (en) | Application of urine alpha 1-antitrypsin and polypeptide fragment thereof in burn | |
| CN113759122A (en) | Application of urine protein Z and polypeptide fragment thereof in burn | |
| CN114113640A (en) | Application of urine blood coagulation factor IX and polypeptide fragment thereof in burn | |
| CN113759133A (en) | Application of urinary angiotensinogen and polypeptide fragment thereof in burn | |
| CN113804889A (en) | Application of Urinary Collagen Type XII α1 Chain and Its Polypeptide Fragments in Burns | |
| CN113777331A (en) | Application of urokininogen-1 and polypeptide fragment thereof in burn | |
| CN113777304A (en) | Application of urine plasminogen and polypeptide fragment thereof in burn | |
| CN113804893A (en) | Application of urine type I collagen alpha 1 chain and polypeptide fragment thereof in burn | |
| CN113804891A (en) | Application of Urine C-reactive Protein and Its Polypeptide Fragments in Burns | |
| CN113777305A (en) | Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn | |
| CN113777303A (en) | Application of urine prothrombin and polypeptide fragment thereof in burn | |
| CN113820485A (en) | Urine carbonic anhydrase 3 and application of polypeptide fragment thereof in burn | |
| CN113759124A (en) | Application of urine alpha 1-antichymotrypsin and polypeptide fragment thereof in burn | |
| CN113804890A (en) | Application of Urine Programmed Cell Death 6-Interacting Protein and Its Polypeptide Fragments in Burns | |
| CN114113601A (en) | Application of urine heparin cofactor II and polypeptide fragment thereof in burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |